AI Article Synopsis
- - Mirvetuximab soravtansine-gynx (Elahere) is an accelerated-approved treatment for adults with certain types of platinum-resistant cancer, specifically if they have folate receptor α-positive epithelial ovarian, fallopian tube, or primary peritoneal cancer, after 1-3 previous treatment regimens.
- - The drug comes with a boxed warning about potential ocular toxicity, meaning it might cause eye problems.
- - Additional warnings highlight risks of pneumonitis (lung inflammation), peripheral neuropathy (nerve damage), and issues related to embryo-fetal toxicity (harm to a fetus during pregnancy).
Article Abstract
Mirvetuximab soravtansine-gynx (Elahere) has been granted accelerated approval to treat adult patients with folate receptor α-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.The drug's labeling includes a boxed warning for ocular toxicity. Other warnings include a risk of pneumonitis, peripheral neuropathy, and embryo-fetal toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000925492.07716.f4 | DOI Listing |
Publication Analysis
Top Keywords
drug treats
4
treats female
4
female reproductive
4
reproductive cancers
4
cancers mirvetuximab
4
mirvetuximab soravtansine-gynx
4
soravtansine-gynx elahere
4
elahere granted
4
granted accelerated
4
accelerated approval
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!